CLAIM #22587 · EMR (EMR) · 2023Q4 earnings call · Nov 7, 2023 · due Nov 7, 2028
“We remain committed to the $165 million of synergies by the end of year five, resulting in approximately 31% adjusted segment EBITDA when moving stock comp to corporate.”
Lal Karsanbhai · CEO
How to check this claim
Look at: NI acquisition run-rate cost synergies achieved, and test & measurement segment adjusted EBITDA margin (with stock comp moved to corporate)
It came true if: Cumulative run-rate synergies >= $165 million AND segment adjusted EBITDA margin >= 31%
Where: Company disclosures / management commentary on NI synergies and segment EBITDA margin (10-K, investor presentations, earnings calls)
In context
“t the rest of the organization, we are also making focused investments in strategic areas. This includes next-generation intelligent devices to further cement our leadership position in our measurement and analytical portfolio, and relevant additions to our sustainability portfolio. At AspenTech, many of the new releases are focused on enabling sustainability and energy transition segments, in addition to further building out capabilities like AI and DataWorks to enable self-optimizing asset management. Please turn to Slide 8. On October 11, we closed the acquisition of NI and announced we will report the business as a new test and measurement segment in 2024. We are very pleased with the progress already in the first month with NI and are excited about the opportunities in this business. We remain committed to the $165 million of synergies by the end of year five, resulting in approximately 31% adjusted segment EBITDA when moving stock comp to corporate. As we have openly stated, NI completes the significant portion of our portfolio transformation, and we are excited to execute as a new company. We will, however, continue to be active with bolt-on acquisitions that fill technology gaps in our business, and we have the balance sheet flexibility to do so. These will be prioritized in four segments we introduced a year ago, industrial software, test and measurement, factory automation, and smart grid solutions. In the fourth quarter, we completed two of these bolt-on acquisitions. Flexim is a global leader for clamp-on ultrasonic technology measuring liquids, gases, and steam. The business is highly complementary to our existing leading flow portfolio consisting of Coriolis, DP Flow, Mag & Vortex, and will also serve attractive growth market”
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2023Q4 earnings call.